Source comparison
BPC-157 vs TB-500: A Side-by-Side Comparison
Placing the two peptides in direct comparison clarifies both why they are paired and how they differ. The contrasts below are what the stacking rationale trades on; the shared bottom rows are what the marketing tends to skip. Origin Synthetic 15-amino-acid fra
This comparison does not assign a generated winner or score.
- Placing the two peptides in direct comparison clarifies both why they are paired and how they differ. The contrasts below are what the stacking rationale trades on; the shared bottom rows are what the marketing tends to skip.
- Origin
- Synthetic 15-amino-acid fragment of a human gastric-juice protein1
- Synthetic actin-binding region of endogenous thymosin beta-4 (43-aa protein)11
- Core proposed mechanism
- Cytoprotection; NO-system stabilization; VEGF-driven angiogenesis; fibroblast FAK-paxillin activation23
- G-actin sequestration → cell migration; ILK-Akt survival; angiogenesis; anti-inflammatory811
- Signature “character”
- Broad, cytoprotective, often framed as localized
- Migration/progenitor-mobilizing, often framed as systemic
- Strongest tissue data
- Tendon and gastrointestinal healing (rodent)35
- Cardiac repair and angiogenesis (rodent, Nature)89
- Human trial data
- None published (no RCTs)6
- Phase 2 for dry eye / wounds (parent protein), not musculoskeletal10
- Independent replication
- Limited; much from one research group
- Broader, incl. major journals for parent molecule
- Oral stability
- Reported stable in gastric juice5
- Not the primary route; typically injectable in research
- FDA approval
- None (unapproved investigational)
- WADA status
- Prohibited at all times (S0)12
- Prohibited (S2, peptide/growth factors)12
- Combination evidence
- None — no controlled study of the two together
- The comparison makes the stacking logic visible in one glance: different origins, different core mechanisms, different signature tissues, and only partial overlap in angiogenesis. That non-redundancy is exactly what a rational combination would want. But the bottom three rows are the reality check — neither is approved, both are banned in sport, and the pairing itself has never been studied. A researcher can appreciate the elegant complementarity in the top half of the table while refusing to let it obscure the empty cell at the bottom. The site’s companion pieces on whether evidence supports BPC-157 as a long-term tendonitis therapy and on whether TB-500 is a promising therapy for chronic inflammatory conditions each drill into one column of this table in more depth.